Squarepoint
NMRA icon

Squarepoint’s Neumora Therapeutics NMRA Stock Holding History

Squarepoint’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$617K Buy
363,145
+206,931
+132% +$394K ﹤0.01% 3262
2026
Q1 		$305K Sell
156,214
-29,618
-16% -$76.7K ﹤0.01% 3690
2025
Q4 		$333K Buy
185,832
+173,061
+1,355% +$379K ﹤0.01% 3518
2025
Q3 		$23.2K Sell
12,771
-2,048
-14% -$3.31K ﹤0.01% 4280
2025
Q2 		$10.9K Sell
14,819
-113,176
-88% -$85.7K ﹤0.01% 4409
2025
Q1 		$128K Buy
+127,995
New +$219K ﹤0.01% 4151

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Squarepoint's NMRA Position: Q2 2026 in Review

Squarepoint increased its Neumora Therapeutics (NMRA) stake by 132% in Q2 2026, buying an estimated $394K and bringing the position to 363,145 shares worth $617K. The position accounts for ﹤0.01% of the portfolio, ranked #3262.

Squarepoint first reported a position in NMRA in Q1 2025 and has held it in 6 quarters since. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Squarepoint held 363,145 shares of Neumora Therapeutics worth $617K as of Q2 2026.
  • Squarepoint bought 206,931 Neumora Therapeutics shares in Q2 2026, an estimated $394K.
  • Neumora Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3262 holding.
  • Squarepoint first reported a position in Neumora Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.